Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceplene plus low-dose IL-2 maintenance in adult AML patients in first complete remission
2009-012083-14Phase 3Completed
- Sponsor
- Meda
- Start
- May 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of histamine dihydrochloride and aldesleukin in acute myeloid leukemia (AML), sponsored by Meda. Primary endpoints: Immune response and Minimal residual disease. Started May 2009; status: completed.
02
Drugs
histamine dihydrochloridealdesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-012083-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012083-14.